Here, we investigated whether baseline serum levels of CXCL10/CCL5 could represent a good surrogate for the treatment response of patients with advanced NSCLC or SCLC treated with PD-L1 inhibitors. The gene discussed is CCL5; the disease is small cell lung carcinoma.